Once the findings in the present study are widely validated in further studies with larger sample sizes, the results will help form a rationale for conducting new clinical trials relevant to adjuvant anti‐DLL3 therapy for DLL3‐positive LCNEC. This evidence concerns the gene DLL3 and large cell neuroendocrine carcinoma.